Related Experiment Videos
[The failures of D penicillamine].
Revue Du Rhumatisme Et Des Maladies Osteo-Articulaires
|March 1, 1978
Summary
D-penicillamine treatment for rheumatoid polyarthritis shows low real success rates, with only a quarter of patients achieving true benefits. Treatment failures stem from inefficacy, patient dropouts, and intolerance.
Area of Science:
- Rheumatology
- Pharmacology
Context:
- Rheumatoid polyarthritis is a chronic autoimmune disease requiring effective treatment.
- D-penicillamine is a therapeutic agent used for rheumatoid polyarthritis.
Purpose:
- To evaluate the real-world efficacy of D-penicillamine in treating rheumatoid polyarthritis.
- To identify factors contributing to treatment failure.
Summary:
- A study of 50 rheumatoid polyarthritis cases treated with D-penicillamine revealed low true success rates.
- Only approximately 25% of patients experienced genuine therapeutic benefit.
- Treatment failures were attributed to overall inefficacy, patient dropouts, and intolerance.
Impact:
- Highlights the limitations of D-penicillamine in rheumatoid polyarthritis management.
- Underscores the need for careful patient selection and monitoring.
- Provides practical data on treatment indications, contraindications, conduct, and supervision.